Free float13 Aug 2018 16:43
Published on the 24th July significant shareholders account for 78% of the shares (not 71% as illustrated on their website) Not accounting for any institution that may have a holding of less than 3% (no declaration needed to the LSE)
Furthermore, I would guess that Directors and employees have about 1%. With 78m shares in issue I would say it is safe to assume that not more than 15m shares are in the hands of the public. Looking over the last 2 years of holdings news, institutional investment average is above the current sp. I would welcome any other poster's calculations but that is the conclusion I have come up with.
The institutions clearly have a controlling vote on what direction the company now takes. Any deal imo would have to be with the backing of the significant shareholders who will be looking at a profit. They may even see a long-term approach bringer richer rewards if and when FLU-5 completes P3 and P4 and possibly bringing in annual royalties that will dwarf our current MC.
The backdrop to all this is the company developing a vaccine for the common cold, asthma and zika, all of which are showing promising research.